Where does Reata Pharmaceuticals Holdings, LLC rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Reata Pharmaceuticals Holdings, LLC ranks #6,831 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Reata Pharmaceuticals Holdings, LLC hold?

Reata Pharmaceuticals Holdings, LLC holds 49 US utility patents granted between 2015 and 2025, spanning 9 technology areas.

What is Reata Pharmaceuticals Holdings, LLC's Innovation Score?

Reata Pharmaceuticals Holdings, LLC has an Innovation Score of 44.9 out of 100 (top 24% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Reata Pharmaceuticals Holdings, LLC focus on?

Reata Pharmaceuticals Holdings, LLC's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 42 patents, ranking #431 of 6,058 assignees active in that subclass. Grants appear in 9 CPC subclasses total.

Is Reata Pharmaceuticals Holdings, LLC's patent grant rate increasing or decreasing?

Reata Pharmaceuticals Holdings, LLC's recent grant velocity is -12% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Reata Pharmaceuticals Holdings, LLC's patents?

Reata Pharmaceuticals Holdings, LLC's patents average 20.2 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Reata Pharmaceuticals Holdings, LLC patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Reata Pharmaceuticals Holdings, LLC

USPTO PatentsView assignee record - 49 granted patents across 9 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Reata ranks #6,831 of 49,997 tracked US assignees by granted-patent volume, with 49 patents across 9 technology areas.

#6,831
of 49,997 US assignees by volume: Top 24%
by Innovation Score (44.9/100): 20.2
avg claims per patent: -12%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R6831 · US Corporation #6,831 · 49 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · VEL-DOWN · BOOK-FULL

GRANTS-SMALL 49 grants
UPPER-Q #6,831/49,997
PHOTO-FINISH Picarro
CPC-NARROW A61P · 9 areas
INNOV-PAR 44.9/100
CLAIMS-DENSE 20.2 claims/avg
TYPE-USCORP US Corporation
VEL-DOWN -12% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Picarro, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Reata’s 44.9 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 13.5 pts (30%) Velocity 8.7 pts (19%) Breadth 10.6 pts (24%) Claim depth 12.1 pts (27%)

Qualcomm Incorporated · highest

85
Central Japan… · near

45
Hobart Brothers · near

45
Reata Pharmaceutical… · this assignee

45
Sophia School · near

45
Vacon OY · near

45
3D Lighting… · lowest

7

What this shows Reata's Innovation Score is 44.9/100 (top 24% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Reata?

Each dot is one of Reata’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Reata’s own 20.2 claims/patent is ABOVE the 15.3 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Reata vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Reata's grants concentrate

Reata Pharmaceuticals Holdings, LLC is a focused PatentsView assignee: 9 CPC subclasses with 85.7% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2015 (6 grants) versus a trough of 2 in 2019. By volume, Reata sits between Picarro, Inc. and SKF Magnetic Mechatronics.

Reata's three-year grant acceleration

Reata Pharmaceuticals Holdings, LLC shows 13 grants in 2022–2024 against only 10 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Picarro

49
Principia Biophar…

49
Pulmonx

49
Qliktech Internat…

49
Rimowa

49
Relievant Medsyst…

49
Seegene

49
SKF Magnetic Mech…

49
Reata Pharmaceuti… ◀

49

What this shows Reata holds 49 patents at rank #6,831, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Reata

By rank, the assignees closest to #6,831 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Reata's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Reata, neither rank-band nor same-CPC leaders (those blocks stay above). In A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…), Reata ranks #431 of 6,058 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (45 here).

Hobart Brothers LLC 45 Vacon OY 45 Central Japan Railway Comany 45 Sophia School Corporation 45

Reata's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

45 Top 24% higher than 76% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Reata Pharmaceuticals Holdings, LLC patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	6	12.2%
2016	6	12.2%
2017	6	12.2%
2018	4	8.2%
2019	2	4.1%
2020	2	4.1%
2021	6	12.2%
2022	4	8.2%
2023	3	6.1%
2024	6	12.2%
2025partial year	4	8.2%

Which technologies does Reata Pharmaceuticals Holdings, LLC patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 42

C07D - Heterocyclic Compounds 31

C07J - Steroids 30

C07C - Acyclic OR Carbocyclic Compounds 24

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 20

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 5

Y02A - Technologies FOR Adaptation TO Climate Change 4

C07F - Acyclic, Carbocyclic OR Heterocyclic Compounds Containing Elements Other Than Carbon, Hydrogen, Halogen, Oxygen, Nitrogen, Sulfur, Selenium OR Tellurium 3

C07H - SUGARS; Derivatives THEREOF; NUCLEOSIDES; NUCLEOTIDES; Nucleic Acids 3

Top 9 of 9 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Reata Pharmaceuticals Holdings, LLC's patent record in context - here's where to go next.

Reata Pharmaceuticals Holdings, LLC's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 85.7% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #6,831 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Reata Pharmaceuticals Holdings, LLC against Picarro, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 44.9/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.